Cortexyme (CRTX) News Today $1.84 +0.07 (+3.95%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsInsider TradesTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cortexyme (NASDAQ:CRTX) Shares Pass Above 200 Day Moving Average - Here's What HappenedCortexyme (NASDAQ:CRTX) Share Price Passes Above 200 Day Moving Average - Here's What HappenedNovember 9, 2024 | marketbeat.comCrism Thera Regulatory NewsAugust 4, 2024 | lse.co.ukCortexyme : Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name - Form 8-K - Marketscreener.comAugust 1, 2022 | marketscreener.comCortexyme Completes Phase 1 Single, Multiple Ascending Dose Trial of Potential Alzheimer's Disease Treatment - Marketscreener.comJuly 27, 2022 | marketscreener.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business WireJuly 27, 2022 | businesswire.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business WireJuly 27, 2022 | businesswire.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Marketscreener.comJuly 27, 2022 | marketscreener.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Yahoo FinanceJuly 27, 2022 | finance.yahoo.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588July 27, 2022 | finance.yahoo.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022July 27, 2022 | finance.yahoo.comCortexyme (CRTX) Announces Resignation of EVP of Research and Development - StreetInsider.comJuly 22, 2022 | streetinsider.comBragar Eagel & Squire, PC Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm - GuruFocus.comJune 26, 2022 | gurufocus.comCortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus In - BenzingaJune 21, 2022 | benzinga.comCortexyme : Preclinical Data Show Efficacy Of COR803 For Coronavirus Infections Treatment - NasdaqJune 21, 2022 | nasdaq.comCortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus InfectionsJune 21, 2022 | finance.yahoo.comCortexyme Appoints June Bray to its Board of Directors - Business WireJune 13, 2022 | businesswire.comCortexyme Appoints June Bray to its Board of Directors - Yahoo FinanceJune 13, 2022 | finance.yahoo.comCortexyme Appoints June Bray to its Board of DirectorsJune 13, 2022 | finance.yahoo.comCortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer - Marketscreener.comJune 11, 2022 | marketscreener.comCortexyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.comJune 10, 2022 | marketscreener.comCortexyme Successfully Completes Acquisition of Novosteo - Business WireMay 22, 2022 | businesswire.comThis Is the Worst Type of Credit Card for Most Consumers - NasdaqMay 20, 2022 | nasdaq.comPPG Showcases Innovations in Paints, Coatings, Specialty Materials That Enhance Sustainability, Efficiency, Mobility - Yahoo FinanceMay 20, 2022 | finance.yahoo.comCortexyme : Completion of Acquisition or Disposition of Assets - Form 8-K - Marketscreener.comMay 20, 2022 | marketscreener.comCortexyme Successfully Completes Acquisition of Novosteo - Yahoo FinanceMay 20, 2022 | finance.yahoo.comCortexyme Appoints Dr. Philip Low to Its Board of DirectorsMay 20, 2022 | finance.yahoo.comPre-market Movers: EBET, AFRM, CELU, FIGS, LLAP… - NasdaqMay 13, 2022 | nasdaq.comCortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases - Yahoo FinanceMay 12, 2022 | finance.yahoo.comCortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic DiseasesMay 12, 2022 | finance.yahoo.comForm 10-Q Cortexyme, Inc. For: Mar 31 - StreetInsider.comMay 11, 2022 | streetinsider.comCortexyme Announces Agreement to Acquire Novosteo - StreetInsider.comMay 11, 2022 | streetinsider.comTuesday Digest: Prologis attempts hostile buyout of Duke; Salesforce's latest buy - San Francisco Business Times - The Business JournalsMay 10, 2022 | bizjournals.comCortexyme Announces Agreement to Acquire NovosteoMay 10, 2022 | finance.yahoo.comBragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the FirmMay 6, 2022 | benzinga.comIs Cortexyme (NASDAQ:CRTX) In A Good Position To Deliver On Growth Plans?May 6, 2022 | finance.yahoo.comBragar Eagel & Squire, PC Is Investigating CareDx, Medallion, Cortexyme, and Corcept and Encourages Investors to Contact the Firm - GuruFocus.comMay 3, 2022 | gurufocus.comThe Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Appl - BenzingaMay 3, 2022 | benzinga.comCortexyme Announces Further Layoffs, Chief Medical Officer LeavesMay 3, 2022 | benzinga.comCORTEXYME, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K) - Marketscreener.comMay 3, 2022 | marketscreener.comBragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and Corcept and Encourages Investors to Contact the FirmMay 1, 2022 | benzinga.comCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - BenzingaApril 28, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating Cortexyme, Corcept, RBB, and Verra and Encourages Investors to Contact the FirmApril 25, 2022 | benzinga.comThinking about buying stock in Cortexyme, Borqs Technologies, Sundial Growers, Nokia, or Nordic American Tanker? - PR NewswireApril 25, 2022 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cortexyme, Inc. - CRTX - BenzingaApril 23, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and SelectQuote and Encourages Investors to Contact the FirmApril 15, 2022 | benzinga.comBragar Eagel & Squire, PC Is Investigating CareDx, Medallion, Cortexyme, and SelectQuote and Encourages Investors to Contact the Firm - GlobeNewswireApril 15, 2022 | globenewswire.comBragar Eagel & Squire, P.C. Is Investigating Medallion, Cortexyme, SelectQuote, and Corcept and Encourage - BenzingaApril 11, 2022 | benzinga.comBragar Eagel & Squire, PC Is Investigating Medallion, - GlobeNewswireApril 10, 2022 | globenewswire.comCortexyme (NASDAQ:CRTX) Downgraded to "Sell" at Zacks Investment ResearchZacks Investment Research downgraded shares of Cortexyme from a "hold" rating to a "sell" rating in a report on Tuesday.March 29, 2022 | marketbeat.comHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Cortexyme, Inc. (CRTX) For Possible Securities Law Violations, Encourages Investors With Significant Losses to Contact Firm - GlobeNewswireMarch 28, 2022 | globenewswire.com Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] CRTX Media Mentions By Week CRTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRTX News Sentiment▼0.000.45▲Average Medical News Sentiment CRTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRTX Articles This Week▼00▲CRTX Articles Average Week Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sangamo Therapeutics News Omnicell News Veradigm News HealthStream News Molecular Partners News Genfit News SOPHiA GENETICS News Inhibrx News Zura Bio News Solid Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
